P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.
Eolia Brissot,Fanny Rialland,Xavier Cahu,M. Strullu,N Corradini,Caroline Thomas,N. Blin,Rialland X,E Thebaud,Patrice Chevallier,Philippe Moreau,Noel-Jean Milpied,J L Harousseau,Francoise Mechinaud,Mohamad Mohty +14 more
TL;DR: Major advances in supportive care practice have been made over the past decade, resulting in a significant survival benefit for the pediatric population undergoing allo-SCT, however, post-transplant relapse remains the leading cause of failure of this therapeutic approach, and preventing relapse represents a major challenge today.
Journal ArticleDOI
Deacetylase inhibitors: an advance in myeloma therapy?
Jacob P. Laubach,Jesús F. San-Miguel,Vania Hungria,Jian Hou,Philippe Moreau,Sagar Lonial,Jae Hoon Lee,Hermann Einsele,Melissa Alsina,Paul G. Richardson +9 more
TL;DR: DACi are a unique and effective new class of agents for the treatment of MM, with panobinostat being the first to have clinically meaningful benefit for patients with relapsed or refractory MM.
Journal ArticleDOI
Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation
Aline Clavert,Zinaida Peric,Eolia Brissot,Florent Malard,Thierry Guillaume,Jacques Delaunay,Viviane Dubruille,Steven Le Gouill,Béatrice Mahé,Thomas Gastinne,Nicolas Blin,Harousseau Jl,Harousseau Jl,Philippe Moreau,Philippe Moreau,Noel Milpied,Noel Milpied,Mohamad Mohty,Mohamad Mohty,Patrice Chevallier +19 more
TL;DR: QOL after RIC is comparable to that seen after myeloablative conditioning, while the natural history of LC after Ric appears to be different from that described in the standard myeloabbative setting, warranting further research in this field.
Journal ArticleDOI
Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.
TL;DR: Evaluated responses using serum free light chain measurements and serum and urine electrophoresis after 2 and 4 cycles of therapy and after stem cell transplantation in 25 light chain and 157 intact immunoglobulin myeloma patients enrolled in the IFM 2007-02 MM trial found good agreement between methods for response assessment.
Journal ArticleDOI
The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma
Paul G. Richardson,Philippe Moreau,Jacob P. Laubach,Neeraj Gupta,Ai Min Hui,Kenneth C. Anderson,Jesús F. San Miguel,Shaji Kumar +7 more
TL;DR: Preliminary data indicate ixazomib is active as a single agent in relapsed/refractory MM and as part of combination regimens in newly diagnosed patients, and Phase III studies in combination with lenalidomide-dexamethasone are ongoing.